Marcondes J A, Minnani S L, Luthold W W, Wajchenberg B L, Samojlik E, Kirschner M A
Hospital das Clinicas, Sao Paolo, Brazil.
Fertil Steril. 1992 Mar;57(3):543-7. doi: 10.1016/s0015-0282(16)54897-3.
To explore the clinical usefulness of the antiandrogen flutamide in the treatment modality for hirsutism in women.
Nine women with hirsutism were assessed before and then monthly for 3 months on a regimen of flutamide 250 mg three times a day as the sole therapeutic agent. Blood samples were taken at each assessment time for a battery of androgenic parameters.
Patients were followed in the Out-Patient Department of the Hospital das Clinicas, Sao Paulo, Brazil. Hormonal assays were performed in the Hormone Laboratories of Hospital das Clinicas and the Endocrine Research Laboratory at Newark Beth Israel Medical Center, Newark, New Jersey.
Nine women with moderate hirsutism were treated with flutamide. Six women were previously diagnosed as having idiopathic hirsutism, and three women were diagnosed as having polycystic ovary syndrome.
All women were treated with flutamide 250 mg three times a day for 3 months.
Improvement of hirsutism was assessed using the Ferriman-Gallwey hair density index. Side effects of drug therapy (deterioration of menses and dry skin) were explored. Androgen parameters included testosterone (T), sex hormone-binding globulin, bound, nonbound, and free T, androstanediol glucuronide, and others.
After 3 months of flutamide alone, Ferriman-Gallwey scores improved in seven of nine women with mean scores decreasing from 28.1 +/- 0.6 to 24.5 +/- 0.6. None of the androgenic parameters changed during this period of time. Follicle-stimulating hormone and luteinizing hormone response to gonadotropin-releasing hormone was unchanged after flutamide.
Flutamide favorably influenced hirsutism in women, with differences noted after only 3 months of therapy. More prolonged and detailed studies of this drug as the sole therapeutic agent for treatment of hirsutism seems warranted.
探讨抗雄激素药物氟他胺在女性多毛症治疗方式中的临床效用。
对9名多毛症女性进行评估，在开始每日三次服用250毫克氟他胺作为唯一治疗药物的方案前及之后的3个月内每月进行一次评估。每次评估时采集血样，检测一系列雄激素参数。
患者在巴西圣保罗Clinicas医院门诊部接受随访。激素检测在Clinicas医院激素实验室以及新泽西州纽瓦克市贝斯以色列医疗中心内分泌研究实验室进行。
9名中度多毛症女性接受氟他胺治疗。6名女性先前被诊断为特发性多毛症，3名女性被诊断为多囊卵巢综合征。
所有女性每日三次服用250毫克氟他胺，持续3个月。
使用费里曼-盖尔韦毛发密度指数评估多毛症的改善情况。探讨药物治疗的副作用（月经紊乱和皮肤干燥）。雄激素参数包括睾酮（T）、性激素结合球蛋白、结合型、非结合型和游离型T、雄烷二醇葡糖苷酸等。
仅使用氟他胺3个月后，9名女性中有7名费里曼-盖尔韦评分有所改善，平均评分从28.1±0.6降至24.5±0.6。在此期间，所有雄激素参数均未改变。氟他胺治疗后，促卵泡生成素和促黄体生成素对促性腺激素释放激素的反应未发生变化。
氟他胺对女性多毛症有积极影响，仅治疗3个月后就有明显差异。作为多毛症唯一治疗药物，对该药物进行更长期、更详细的研究似乎很有必要。
